Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply
Rhea-AI Summary
Sanuwave (NASDAQ: SNWV) announced that its UltraMIST wound-care system has been added to Healogics iSupply, the Healogics Group Purchasing Organization, making UltraMIST an option for iSupply members including Wound Care Centers, home health agencies, and skilled nursing facilities.
Sanuwave said it plans to roll out the UltraMIST system to initial iSupply locations by the end of 2025. The companies described the arrangement as a collaboration intended to provide a cost-saving, FDA-approved wound healing option to Healogics members.
Positive
- GPO listing: UltraMIST added to Healogics iSupply
- Rollout timeline: initial locations by end of 2025
Negative
- None.
Market Reality Check
Peers on Argus
Peers showed mixed moves: TCMD up 3.41%, while CLPT, NPCE, and DCTH fell between 2–4%, and RXST was modestly positive. This contrasts with SNWV’s pre-news decline of 4.09%, suggesting stock-specific factors.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2025-11-07 | Earnings results | Positive | +17.7% | Record Q3 2025 revenue, strong margins and positive earnings metrics. |
| 2025-11-03 | Earnings call notice | Neutral | +0.3% | Announcement of timing and access details for Q3 results call. |
| 2025-11-03 | Reimbursement update | Neutral | -5.3% | CMS final rule keeping UltraMIST reimbursement materially unchanged. |
| 2025-10-06 | Preliminary earnings | Neutral | +9.1% | Preliminary record Q3 revenue with lowered full‑year guidance. |
| 2025-09-26 | Debt refinancing | Neutral | -1.2% | New credit facility replacing prior debt with J.P. Morgan financing. |
Recent fundamentally positive or neutral updates often saw positive reactions, but regulatory/structural news has sometimes produced downside or mixed responses.
Over the last few months, Sanuwave reported record Q3 2025 revenue of $11.5M with strong growth and profitability, which was followed by a notably positive share reaction. Earlier, preliminary Q3 revenue and reduced full‑year guidance still led to a gain, while a CMS fee schedule update for UltraMIST produced a negative move despite largely unchanged reimbursement. Debt refinancing via a new credit facility had a mildly negative reaction. Today’s Healogics iSupply GPO addition builds on prior UltraMIST reimbursement clarity and recent commercial momentum.
Market Pulse Summary
This announcement adds Sanuwave’s UltraMIST system to the Healogics iSupply group purchasing organization, making it an option for wound care centers, home health agencies, and skilled nursing facilities by the end of 2025. In context of recent record Q3 2025 revenue of $11.5M and stable CMS reimbursement for UltraMIST, the news highlights continued commercial channel expansion. Investors may watch utilization trends, contract penetration within Healogics’ network, and future updates on revenue mix from UltraMIST.
Key Terms
group purchasing organization financial
gpo financial
AI-generated analysis. Not financial advice.
Healogics Wound Care Supply adds UltraMIST to its Group Purchasing Organization
Healogics iSupply and Sanuwave collaborate to provide UltraMIST as an option for GPO members
EDEN PRAIRIE, Minn., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of its UltraMIST product line to Healogics iSupply. With this expansion, UltraMIST becomes an option for iSupply members, including Wound Care Centers®, home health agencies, and skilled nursing facilities.
Sanuwave plans to roll out the UltraMIST system to Healogics iSupply members at initial locations by the end of 2025.
“We’re excited to collaborate with Healogics, the nation’s leader in wound care treatment and research,” said Morgan Frank, Sanuwave CEO. “Their network is one of the preeminent organizations in advanced wound care, and the opportunity to offer the UltraMIST product to its members and to collaborate with such a well-respected group is a fantastic opportunity for us, and we look forward to working with them.”
Richard Galentino, President of Healogics Wound Care Supply added, “We continue to look for opportunities to partner with innovative organizations focused on wound healing technologies. We are excited that Sanuwave will be joining our GPO and providing our members with a cost-saving solution that is best-in-class from a patient care perspective.”
About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
About Healogics
For nearly 30 years, Healogics has led the nation in advanced wound care, transforming lives through evidence-based treatment and innovation. Guided by its mission to FIND. TREAT. HEAL.™, Healogics partners with hospitals and health systems across the country to deliver specialized care for patients with chronic wounds. Backed by the world’s largest wound care outcomes database and the Wound Science Initiative, Healogics continues to advance research and set new standards in healing. Learn more at www.healogics.com.
As the industry leader, Healogics has the largest repository of chronic wound-specific patient data in the country. The Healogics Wound Science Initiative offers peer-reviewed research and advanced analytics in the pursuit of not only better outcomes, but a better way to provide care.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, except as may be required by applicable law.
Contact: investors@sanuwave.com
FAQ
What did Sanuwave (SNWV) announce on December 8, 2025 regarding UltraMIST?
Which types of facilities will have access to UltraMIST through Healogics iSupply for SNWV?
When will Sanuwave start rolling out UltraMIST to Healogics iSupply locations?
How does the Healogics iSupply listing affect SNWV distribution?
Is UltraMIST FDA approved as stated in the Sanuwave announcement for SNWV?
